TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.

Autor: Kabirian R; Department of Medical Oncology, Gustave Roussy, Villejuif, & GINECO, France., Tredan O; Centre Léon Bérard, Lyon, & GINECO, France., Marmé F; Medical Faculty Mannheim, Heidelberg University & AGO Study Group, Germany., Paoletti X; Biostatistic Unit, Institut Curie, Paris, France., Eberst L; Institut de Cancérologie de Strasbourg Europe, ICANS, Strasbourg, & GINECO, France., Lebreton C; Institut Bergonié, Bordeaux, & GINECO, France., De La Motte Rouge T; Centre Eugène Marquis, Rennes, & GINECO, France., Sabatier R; Aix-Marseille Univ, CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Department of Medical Oncology, Marseille, & GINECO, France., Angelergues A; Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, & GINECO, France., Fabbro M; Institut du Cancer de Montpellier (ICM), Montpellier, & GINECO, France., Van Gorp T; Leuven Cancer Institute, Division of Gynaecological Oncology, University Hospital Leuven, BGOG, Belgium., Mansi L; CHU Besançon - Hôpital jean Minjoz, Besançon, & GINECO, France., Gladieff L; Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, & GINECO, France., Kaczmarek E; Centre Oscar Lambret, Lille, & GINECO, France., Alexandre J; Université de Paris Cité, AP-HP, Hôpital Cochin, Paris, & GINECO, France., Grellety T; Centre Hospitalier de la Côte Basque, Bayonne, & GINECO, France., Favier L; Centre Georges François Leclerc, Dijon, & GINECO, France., Welz J; Evang. Kliniken Essen-Mitte - ESSEN & AGO Study Group, Germany., Frenel JS; Institut de Cancérologie de l'Ouest, Centre René Gauducheau, 44800, Saint Herblain, & GINECO, France., Leary A; Department of Medical Oncology, Gustave Roussy, Villejuif, & GINECO, France.
Jazyk: angličtina
Zdroj: Future oncology (London, England) [Future Oncol] 2024; Vol. 20 (35), pp. 2699-2708. Date of Electronic Publication: 2024 Aug 19.
DOI: 10.1080/14796694.2024.2386922
Abstrakt: Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are offered to prolong intervals between lines of chemotherapy. Current maintenance options involve bevacizumab and poly ADP-ribose polymerase inhibitors, but these lines of therapy can only be used once in the disease course. Patients in first or second platinum sensitive relapse after poly ADP-ribose polymerase inhibitors and bevacizumab represent an area of unmet medical need. This academic sponsored, international Phase II randomized trial is evaluating the combination of a therapeutic cancer vaccine (OSE2101) with anti-PD1 (pembrolizumab) as maintenance therapy, in patients with platinum-sensitive recurrence regardless of number of prior lines and no progression after platinum-based chemotherapy. Clinical Trial Registration: NCT04713514 (ClinicalTrials.gov).
Databáze: MEDLINE